<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240702222707&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240702222707&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 03 Jul 2024 02:27:08 +0000</lastbuilddate>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A notion of bioprosthetic aortic valve durability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae387. doi: 10.1093/eurheartj/ehae387. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953858</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae387>10.1093/eurheartj/ehae387</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953858</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Lars Søndergaard</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A notion of bioprosthetic aortic valve durability</dc:title>
<dc:identifier>pmid:38953858</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae387</dc:identifier>
</item>
<item>
<title>Endometrial stromal sarcoma with intracardiac extension through inferior vena cava</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae391. doi: 10.1093/eurheartj/ehae391. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae391>10.1093/eurheartj/ehae391</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953792</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhitong Ge</dc:creator>
<dc:creator>Xiao Yang</dc:creator>
<dc:creator>Jianchu Li</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Endometrial stromal sarcoma with intracardiac extension through inferior vena cava</dc:title>
<dc:identifier>pmid:38953792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae391</dc:identifier>
</item>
<item>
<title>What influences the bleeding risk of long-term anticoagulation after catheter ablation in patients with atrial fibrillation at high risk of thromboembolism?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae388. doi: 10.1093/eurheartj/ehae388. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953790</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae388>10.1093/eurheartj/ehae388</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953790</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lingyan Lv</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>What influences the bleeding risk of long-term anticoagulation after catheter ablation in patients with atrial fibrillation at high risk of thromboembolism?</dc:title>
<dc:identifier>pmid:38953790</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae388</dc:identifier>
</item>
<item>
<title>Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Higher MVPA volume was associated with a lower risk of developing AS and subsequent AS-related intervention or mortality. Future research needs to validate these findings in diverse populations with longer durations and repeated periods of activity monitoring.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae406. doi: 10.1093/eurheartj/ehae406. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Physical activity has proven effective in preventing atherosclerotic cardiovascular disease, but its role in preventing degenerative valvular heart disease (VHD) remains uncertain. This study aimed to explore the dose-response association between moderate to vigorous physical activity (MVPA) volume and the risk of degenerative VHD among middle-aged adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A full week of accelerometer-derived MVPA data from 87 248 UK Biobank participants (median age 63.3, female: 56.9%) between 2013 and 2015 were used for primary analysis. Questionnaire-derived MVPA data from 361 681 UK Biobank participants (median age 57.7, female: 52.7%) between 2006 and 2010 were used for secondary analysis. The primary outcome was the diagnosis of incident degenerative VHD, including aortic valve stenosis (AS), aortic valve regurgitation (AR), and mitral valve regurgitation (MR). The secondary outcome was VHD-related intervention or mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the accelerometer-derived MVPA cohort, 555 incident AS, 201 incident AR, and 655 incident MR occurred during a median follow-up of 8.11 years. Increased MVPA volume showed a steady decline in AS risk and subsequent AS-related intervention or mortality risk, levelling off beyond approximately 300 min/week. In contrast, its association with AR or MR incidence was less apparent. The adjusted rates of AS incidence (95% confidence interval) across MVPA quartiles (Q1-Q4) were 11.60 (10.20, 13.20), 7.82 (6.63, 9.23), 5.74 (4.67, 7.08), and 5.91 (4.73, 7.39) per 10 000 person-years. The corresponding adjusted rates of AS-related intervention or mortality were 4.37 (3.52, 5.43), 2.81 (2.13, 3.71), 1.93 (1.36, 2.75), and 2.14 (1.50, 3.06) per 10 000 person-years, respectively. Aortic valve stenosis risk reduction was also observed with questionnaire-based MVPA data [adjusted absolute difference Q4 vs. Q1: AS incidence, -1.41 (-.67, -2.14) per 10 000 person-years; AS-related intervention or mortality, -.38 (-.04, -.88) per 10 000 person-years]. The beneficial association remained consistent in high-risk populations for AS, including patients with hypertension, obesity, dyslipidaemia, and chronic kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Higher MVPA volume was associated with a lower risk of developing AS and subsequent AS-related intervention or mortality. Future research needs to validate these findings in diverse populations with longer durations and repeated periods of activity monitoring.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953786</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae406>10.1093/eurheartj/ehae406</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953786</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziang Li</dc:creator>
<dc:creator>Sijing Cheng</dc:creator>
<dc:creator>Bo Guo</dc:creator>
<dc:creator>Lu Ding</dc:creator>
<dc:creator>Yu Liang</dc:creator>
<dc:creator>Yinghan Shen</dc:creator>
<dc:creator>Jinyue Li</dc:creator>
<dc:creator>Yiqing Hu</dc:creator>
<dc:creator>Tianxin Long</dc:creator>
<dc:creator>Xinli Guo</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Runlin Gao</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Bin Zhang</dc:creator>
<dc:creator>Haiyan Xu</dc:creator>
<dc:creator>Marie-Annick Clavel</dc:creator>
<dc:creator>Yongjian Wu</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis</dc:title>
<dc:identifier>pmid:38953786</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae406</dc:identifier>
</item>
<item>
<title>Primary cardiac lymphoma causing coronary artery compression and massive tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae390. doi: 10.1093/eurheartj/ehae390. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae390>10.1093/eurheartj/ehae390</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953783</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Munehisa Bekki</dc:creator>
<dc:creator>Nobuhiro Tahara</dc:creator>
<dc:creator>Yoshihiro Fukumoto</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Primary cardiac lymphoma causing coronary artery compression and massive tricuspid regurgitation</dc:title>
<dc:identifier>pmid:38953783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae390</dc:identifier>
</item>
<item>
<title>Oral anticoagulant use after catheter ablation for atrial fibrillation based on thrombo-embolic risk: future studies will be needed for bleeding high-risk group</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae389. doi: 10.1093/eurheartj/ehae389. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae389>10.1093/eurheartj/ehae389</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953778</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Koshiro Kanaoka</dc:creator>
<dc:creator>Yoshitaka Iwanaga</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oral anticoagulant use after catheter ablation for atrial fibrillation based on thrombo-embolic risk: future studies will be needed for bleeding high-risk group</dc:title>
<dc:identifier>pmid:38953778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae389</dc:identifier>
</item>
<item>
<title>Atrial fibrillation burden: a new outcome predictor and therapeutic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden is associated with a lower risk of stroke and heart failure in patients with AF: stroke risk...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae373. doi: 10.1093/eurheartj/ehae373. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden is associated with a lower risk of stroke and heart failure in patients with AF: stroke risk without anticoagulation is lower in patients with device-detected AF and a low AF burden (stroke rate 1%/year) than in patients with persistent and permanent AF (stroke rate 3%/year). Paroxysmal AF shows intermediate stroke rates (2%/year). Atrial fibrillation burden-reducing interventions can reduce cardiovascular outcomes in patients with AF: early rhythm control reduces cardiovascular events including stroke and heart failure in patients with recently diagnosed AF and cardiovascular conditions. In patients with heart failure and AF, early rhythm control and AF ablation, interventions that reduce AF burden, reduce mortality and heart failure events. Recent technological innovations allow to estimate AF burden in clinical care, creating opportunities and challenges. While evidence remains limited, the existing data already suggest that AF burden reduction could be a therapeutic goal. In addition to anticoagulation and treatment of cardiovascular conditions, AF burden reduction emerges as a therapeutic goal. Future research will define the AF burden that constitutes a relevant risk of stroke and heart failure. Technologies quantifying AF burden need careful validation to advance the field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953776</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae373>10.1093/eurheartj/ehae373</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953776</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>Andreas Metzner</dc:creator>
<dc:creator>Tobias Toennis</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation burden: a new outcome predictor and therapeutic target</dc:title>
<dc:identifier>pmid:38953776</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae373</dc:identifier>
</item>
<item>
<title>Long-term outcomes of transcatheter vs. surgical aortic valve replacement: is there still a question to be answered?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae386. doi: 10.1093/eurheartj/ehae386. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953773</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae386>10.1093/eurheartj/ehae386</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953773</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kyriakos Dimitriadis</dc:creator>
<dc:creator>Nikolaos Pyrpyris</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term outcomes of transcatheter vs. surgical aortic valve replacement: is there still a question to be answered?</dc:title>
<dc:identifier>pmid:38953773</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae386</dc:identifier>
</item>
<item>
<title>Secondary tricuspid regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38953772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: New-onset AFib vs. SR conferred a higher risk of the individual TR types related to sequelae of AFib and higher pacemaker implantation rates, although the distribution of TR types was similar. Secondary TR was universally associated with increased mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 2:ehae346. doi: 10.1093/eurheartj/ehae346. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Incidence and types of secondary tricuspid regurgitation (TR) are not well defined in atrial fibrillation (AFib) and sinus rhythm (SR). Atrial secondary TR (A-STR) is associated with pre-existing AFib; however, close to 50% of patients with A-STR do not have AFib. The aim of this study was to assess incidence, types, and outcomes of ≥ moderate TR in AFib vs. SR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adults with and without new-onset AFib without structural heart disease or ≥ moderate TR at baseline were followed for the development of ≥ moderate TR. Tricuspid regurgitation types were pacemaker, left-sided valve disease, left ventricular (LV) dysfunction, pulmonary hypertension (PH), isolated ventricular, and A-STR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1359 patients with AFib and 20 438 in SR, 109 and 378 patients developed ≥ moderate TR, respectively. The individual types of TR occurred more frequently in AFib related to the higher pacemaker implantation rates (1.12 vs. 0.19 per 100 person-years, P &lt; .001), larger right atrial size (median 78 vs. 53 mL, P &lt; .001), and higher pulmonary pressures (median 30 vs. 28 mmHg, P &lt; .001). The most common TR types irrespective of rhythm were LV dysfunction-TR and A-STR. Among patients in SR, those with A-STR were older, predominantly women with more diastolic abnormalities and higher pulmonary pressures. All types of secondary TR were associated with all-cause mortality, highest in PH-TR and LV dysfunction-TR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: New-onset AFib vs. SR conferred a higher risk of the individual TR types related to sequelae of AFib and higher pacemaker implantation rates, although the distribution of TR types was similar. Secondary TR was universally associated with increased mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38953772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38953772</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae346>10.1093/eurheartj/ehae346</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38953772</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Matteo Castrichini</dc:creator>
<dc:creator>Hossam H Ibrahim</dc:creator>
<dc:creator>Christopher G Scott</dc:creator>
<dc:creator>Grace Lin</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Rekha Mankad</dc:creator>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Mackram F Eleid</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Secondary tricuspid regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm</dc:title>
<dc:identifier>pmid:38953772</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae346</dc:identifier>
</item>
<item>
<title>A New Molecular Axis to Tackle the Development of Abdominal Aortic Aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950116/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):47-48. doi: 10.1161/CIRCULATIONAHA.124.069916. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950116/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950116</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069916>10.1161/CIRCULATIONAHA.124.069916</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950116</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Leonardo Elia</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A New Molecular Axis to Tackle the Development of Abdominal Aortic Aneurysm</dc:title>
<dc:identifier>pmid:38950116</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069916</dc:identifier>
</item>
<item>
<title>Correction to: Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e20. doi: 10.1161/CIR.0000000000001267. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950115</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001267>10.1161/CIR.0000000000001267</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950115</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial</dc:title>
<dc:identifier>pmid:38950115</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001267</dc:identifier>
</item>
<item>
<title>Response by Berry et al to Letter Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e5-e6. doi: 10.1161/CIRCULATIONAHA.124.069708. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950114</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069708>10.1161/CIRCULATIONAHA.124.069708</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950114</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Novalia P Sidik</dc:creator>
<dc:creator>Margaret B McEntegart</dc:creator>
<dc:creator>CorCTA Investigators</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Berry et al to Letter Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38950114</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069708</dc:identifier>
</item>
<item>
<title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):1-3. doi: 10.1161/CIR.0000000000001271. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950113</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001271>10.1161/CIR.0000000000001271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950113</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38950113</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001271</dc:identifier>
</item>
<item>
<title>Health and Hope for Everyone, Everywhere, Starts With Access to Health Care: The Role of Medicaid Expansion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e1-e2. doi: 10.1161/CIRCULATIONAHA.124.070084. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950112</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070084>10.1161/CIRCULATIONAHA.124.070084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950112</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Dan Jones</dc:creator>
<dc:creator>Cheryl Pegus</dc:creator>
<dc:creator>Janay C Johnson</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Health and Hope for Everyone, Everywhere, Starts With Access to Health Care: The Role of Medicaid Expansion</dc:title>
<dc:identifier>pmid:38950112</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070084</dc:identifier>
</item>
<item>
<title>Letter by Nishi et al Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):e3-e4. doi: 10.1161/CIRCULATIONAHA.124.068798. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950111</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068798>10.1161/CIRCULATIONAHA.124.068798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950111</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeshi Nishi</dc:creator>
<dc:creator>Yuichi Saito</dc:creator>
<dc:creator>Yoshio Kobayashi</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Nishi et al Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial"</dc:title>
<dc:identifier>pmid:38950111</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068798</dc:identifier>
</item>
<item>
<title>Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):62-79. doi: 10.1161/CIRCULATIONAHA.124.068885. Epub 2024 Jul 1.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol targets or triggers to initiate treatment change, consistent targets for apoB are lacking. In this review, we synthesize existing data regarding the epidemiology of apoB by comparing guideline recommendations regarding use of apoB measurement, describing population percentiles of apoB relative to low-density lipoprotein cholesterol levels, summarizing studies of discordance between low-density lipoprotein cholesterol and apoB levels, and evaluating apoB levels in clinical trials of lipid-lowering therapy to guide potential treatment targets. We propose evidence-guided apoB thresholds for use in cholesterol management and clinical care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950110</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068885>10.1161/CIRCULATIONAHA.124.068885</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950110</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Diana De Oliveira-Gomes</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Anand Rohatgi</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice</dc:title>
<dc:identifier>pmid:38950110</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068885</dc:identifier>
</item>
<item>
<title>Ablation of Cardiac Arrhythmias: Past, Present, and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):4-6. doi: 10.1161/CIRCULATIONAHA.124.068298. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950109</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068298>10.1161/CIRCULATIONAHA.124.068298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950109</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Hakan Oral</dc:creator>
<dc:creator>Fred Morady</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ablation of Cardiac Arrhythmias: Past, Present, and Future</dc:title>
<dc:identifier>pmid:38950109</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068298</dc:identifier>
</item>
<item>
<title>Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38950107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 2;150(1):82-85. doi: 10.1161/CIRCULATIONAHA.123.066709. Epub 2024 Jul 1.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38950107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38950107</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066709>10.1161/CIRCULATIONAHA.123.066709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38950107</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro Gabriel Melo de Barros E Silva</dc:creator>
<dc:creator>Ariane Vieira Scarlatelli Macedo</dc:creator>
<dc:creator>Bruna Bronhara</dc:creator>
<dc:creator>Lucas Petri Damiani</dc:creator>
<dc:creator>Lilian Mazza Barbosa</dc:creator>
<dc:creator>Nathália Rodrigues Lopes</dc:creator>
<dc:creator>Mayra Akimi Suiama</dc:creator>
<dc:creator>Murillo O Antunes</dc:creator>
<dc:creator>Mariana Raquel Gonçalves</dc:creator>
<dc:creator>Otávio Celso Eluf Gebara</dc:creator>
<dc:creator>Priscilla de Aquino Martins</dc:creator>
<dc:creator>Mariana Galvão Ribeiro</dc:creator>
<dc:creator>João Batista de Moura Xavier de Moraes</dc:creator>
<dc:creator>Valéria Cristina Resende Aguiar</dc:creator>
<dc:creator>Alexandre B Cavalcanti</dc:creator>
<dc:creator>Regis G Rosa</dc:creator>
<dc:creator>Otavio Berwanger</dc:creator>
<dc:creator>Viviane C Veiga</dc:creator>
<dc:creator>Luciano C P Azevedo</dc:creator>
<dc:creator>Eduardo Ramacciotti</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Alvaro Avezum</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Coalition COVID-19 Brazil Investigators</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38950107</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066709</dc:identifier>
</item>
<item>
<title>Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38946541/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ARRDC4 serves as a regulator of hyperglycemia-induced toxicities toward cardiac and skeletal muscle, revealing a new molecular framework that connects hyperglycemia to cardiac/skeletal myopathy to exercise intolerance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 1. doi: 10.1161/CIRCRESAHA.123.323158. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exercise intolerance is an independent predictor of poor prognosis in diabetes. The underlying mechanism of the association between hyperglycemia and exercise intolerance remains undefined. We recently demonstrated that the interaction between ARRDC4 (arrestin domain-containing protein 4) and GLUT1 (glucose transporter 1) regulates cardiac metabolism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether this mechanism broadly impacts diabetic complications, we investigated the role of ARRDC4 in the pathogenesis of diabetic cardiac and skeletal myopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: High glucose promoted translocation of MondoA into the nucleus, which upregulated <i>Arrdc4</i> transcriptional expression, increased lysosomal GLUT1 trafficking, and blocked glucose transport in cardiomyocytes, forming a feedback mechanism. This role of <i>ARRDC4</i> was confirmed in human muscular cells from type 2 diabetic patients. Prolonged hyperglycemia upregulated myocardial <i>Arrdc4</i> expression in multiple types of mouse models of diabetes. We then analyzed hyperglycemia-induced cardiac and skeletal muscle abnormalities in insulin-deficient mice. Hyperglycemia increased advanced glycation end-products and elicited oxidative and endoplasmic reticulum stress leading to apoptosis in the heart and peripheral muscle. However, deletion of <i>Arrdc4</i> augmented tissue glucose transport and mitochondrial respiration, protecting the heart and muscle from tissue damage. Stress hemodynamic analysis and treadmill exhaustion test uncovered that <i>Arrdc4</i>-knockout mice had greater cardiac inotropic/chronotropic reserve with higher exercise endurance than wild-type (WT) animals under diabetes. While multiple organs were involved in the mechanism, cardiac-specific overexpression (beyond levels observed during diabetes) using adenoassociated virus suggests that high levels of myocardial <i>ARRDC4</i> have the potential to contribute to exercise intolerance by interfering with cardiac metabolism through its interaction with GLUT1 in diabetes. Importantly, the <i>ARRDC4</i> mutation mouse line exhibited greater exercise tolerance, showing the potential therapeutic impact on diabetic cardiomyopathy by disrupting the interaction between ARRDC4 and GLUT1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ARRDC4 serves as a regulator of hyperglycemia-induced toxicities toward cardiac and skeletal muscle, revealing a new molecular framework that connects hyperglycemia to cardiac/skeletal myopathy to exercise intolerance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38946541/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38946541</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323158>10.1161/CIRCRESAHA.123.323158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38946541</guid>
<pubDate>Mon, 01 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yoshinobu Nakayama</dc:creator>
<dc:creator>Satoru Kobayashi</dc:creator>
<dc:creator>Aliya Masihuddin</dc:creator>
<dc:creator>Syed Amir Abdali</dc:creator>
<dc:creator>A M Pramodh Bandara Seneviratne</dc:creator>
<dc:creator>Sachiyo Ishii</dc:creator>
<dc:creator>Jun Iida</dc:creator>
<dc:creator>Qiangrong Liang</dc:creator>
<dc:creator>Jun Yoshioka</dc:creator>
<dc:date>2024-07-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes</dc:title>
<dc:identifier>pmid:38946541</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323158</dc:identifier>
</item>
<item>
<title>Temporal dynamics of woolly mammoth genome erosion prior to extinction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>A number of species have recently recovered from near-extinction. Although these species have avoided the immediate extinction threat, their long-term viability remains precarious due to the potential genetic consequences of population declines, which are poorly understood on a timescale beyond a few generations. Woolly mammoths (Mammuthus primigenius) became isolated on Wrangel Island around 10,000 years ago and persisted for over 200 generations before becoming extinct around 4,000 years ago....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 17:S0092-8674(24)00577-4. doi: 10.1016/j.cell.2024.05.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A number of species have recently recovered from near-extinction. Although these species have avoided the immediate extinction threat, their long-term viability remains precarious due to the potential genetic consequences of population declines, which are poorly understood on a timescale beyond a few generations. Woolly mammoths (Mammuthus primigenius) became isolated on Wrangel Island around 10,000 years ago and persisted for over 200 generations before becoming extinct around 4,000 years ago. To study the evolutionary processes leading up to the mammoths' extinction, we analyzed 21 Siberian woolly mammoth genomes. Our results show that the population recovered quickly from a severe bottleneck and remained demographically stable during the ensuing six millennia. We find that mildly deleterious mutations gradually accumulated, whereas highly deleterious mutations were purged, suggesting ongoing inbreeding depression that lasted for hundreds of generations. The time-lag between demographic and genetic recovery has wide-ranging implications for conservation management of recently bottlenecked populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38942016</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.033>10.1016/j.cell.2024.05.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942016</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marianne Dehasque</dc:creator>
<dc:creator>Hernán E Morales</dc:creator>
<dc:creator>David Díez-Del-Molino</dc:creator>
<dc:creator>Patrícia Pečnerová</dc:creator>
<dc:creator>J Camilo Chacón-Duque</dc:creator>
<dc:creator>Foteini Kanellidou</dc:creator>
<dc:creator>Héloïse Muller</dc:creator>
<dc:creator>Valerii Plotnikov</dc:creator>
<dc:creator>Albert Protopopov</dc:creator>
<dc:creator>Alexei Tikhonov</dc:creator>
<dc:creator>Pavel Nikolskiy</dc:creator>
<dc:creator>Gleb K Danilov</dc:creator>
<dc:creator>Maddalena Giannì</dc:creator>
<dc:creator>Laura van der Sluis</dc:creator>
<dc:creator>Tom Higham</dc:creator>
<dc:creator>Peter D Heintzman</dc:creator>
<dc:creator>Nikolay Oskolkov</dc:creator>
<dc:creator>M Thomas P Gilbert</dc:creator>
<dc:creator>Anders Götherström</dc:creator>
<dc:creator>Tom van der Valk</dc:creator>
<dc:creator>Sergey Vartanyan</dc:creator>
<dc:creator>Love Dalén</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Temporal dynamics of woolly mammoth genome erosion prior to extinction</dc:title>
<dc:identifier>pmid:38942016</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.033</dc:identifier>
</item>
<item>
<title>The extracellular matrix integrates mitochondrial homeostasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38942015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240702222707&amp;v=2.18.0.post9+e462414
      <description>Cellular homeostasis is intricately influenced by stimuli from the microenvironment, including signaling molecules, metabolites, and pathogens. Functioning as a signaling hub within the cell, mitochondria integrate information from various intracellular compartments to regulate cellular signaling and metabolism. Multiple studies have shown that mitochondria may respond to various extracellular signaling events. However, it is less clear how changes in the extracellular matrix (ECM) can impact...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 24:S0092-8674(24)00638-X. doi: 10.1016/j.cell.2024.05.057. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular homeostasis is intricately influenced by stimuli from the microenvironment, including signaling molecules, metabolites, and pathogens. Functioning as a signaling hub within the cell, mitochondria integrate information from various intracellular compartments to regulate cellular signaling and metabolism. Multiple studies have shown that mitochondria may respond to various extracellular signaling events. However, it is less clear how changes in the extracellular matrix (ECM) can impact mitochondrial homeostasis to regulate animal physiology. We find that ECM remodeling alters mitochondrial homeostasis in an evolutionarily conserved manner. Mechanistically, ECM remodeling triggers a TGF-β response to induce mitochondrial fission and the unfolded protein response of the mitochondria (UPR<sup>MT</sup>). At the organismal level, ECM remodeling promotes defense of animals against pathogens through enhanced mitochondrial stress responses. We postulate that this ECM-mitochondria crosstalk represents an ancient immune pathway, which detects infection- or mechanical-stress-induced ECM damage, thereby initiating adaptive mitochondria-based immune and metabolic responses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38942015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240702222707&v=2.18.0.post9+e462414">38942015</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.057>10.1016/j.cell.2024.05.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38942015</guid>
<pubDate>Fri, 28 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Hanlin Zhang</dc:creator>
<dc:creator>C Kimberly Tsui</dc:creator>
<dc:creator>Gilberto Garcia</dc:creator>
<dc:creator>Larry K Joe</dc:creator>
<dc:creator>Haolun Wu</dc:creator>
<dc:creator>Ayane Maruichi</dc:creator>
<dc:creator>Wudi Fan</dc:creator>
<dc:creator>Sentibel Pandovski</dc:creator>
<dc:creator>Peter H Yoon</dc:creator>
<dc:creator>Brant M Webster</dc:creator>
<dc:creator>Jenni Durieux</dc:creator>
<dc:creator>Phillip A Frankino</dc:creator>
<dc:creator>Ryo Higuchi-Sanabria</dc:creator>
<dc:creator>Andrew Dillin</dc:creator>
<dc:date>2024-06-28</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The extracellular matrix integrates mitochondrial homeostasis</dc:title>
<dc:identifier>pmid:38942015</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.057</dc:identifier>
</item>





























</channel>
</rss>